Published in Nat Rev Clin Oncol on October 01, 2009
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat Chem Biol (2012) 2.41
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene (2010) 1.88
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol (2013) 1.77
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis (2011) 1.68
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer (2010) 1.63
EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer (2012) 1.63
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev (2012) 1.60
The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. J Exp Med (2014) 1.59
Signaling pathways in renal cell carcinoma. Cancer Biol Ther (2010) 1.58
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis (2011) 1.53
CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS One (2013) 1.51
HGF-independent potentiation of EGFR action by c-Met. Oncogene (2011) 1.46
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci (2011) 1.45
Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol (2011) 1.38
Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A (2013) 1.37
Targeting metastasis. Nat Rev Cancer (2016) 1.26
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog (2010) 1.24
Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest (2011) 1.20
Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCα invasive signaling axis. Sci Signal (2012) 1.19
Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res (2010) 1.18
The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene (2011) 1.17
Tumor cell migration in complex microenvironments. Cell Mol Life Sci (2012) 1.16
Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res (2011) 1.16
Chromium genotoxicity: A double-edged sword. Chem Biol Interact (2010) 1.14
Modulation of tight junction structure and function by kinases and phosphatases targeting occludin. J Biomed Biotechnol (2012) 1.12
Impacts of environmental toxicants on male reproductive dysfunction. Trends Pharmacol Sci (2011) 1.11
MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience (2014) 1.10
Targeting invadopodia to block breast cancer metastasis. Oncotarget (2011) 1.10
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs (2012) 1.09
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget (2014) 1.07
Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene (2012) 1.06
Src family kinases and paclitaxel sensitivity. Cancer Biol Ther (2011) 1.05
Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci U S A (2011) 1.03
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res (2010) 1.02
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. Oncogene (2011) 1.01
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res (2012) 0.99
Src modulates contractile vascular smooth muscle function via regulation of focal adhesions. J Cell Physiol (2012) 0.98
Pro-nerve growth factor induces autocrine stimulation of breast cancer cell invasion through tropomyosin-related kinase A (TrkA) and sortilin protein. J Biol Chem (2011) 0.98
miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. PLoS One (2014) 0.98
PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells. J Biol Chem (2010) 0.98
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells. Mol Cell Biol (2011) 0.97
Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol Carcinog (2013) 0.97
Targeting allosteric disulphide bonds in cancer. Nat Rev Cancer (2013) 0.96
Roles for crk in cancer metastasis and invasion. Genes Cancer (2012) 0.96
Phosphoregulation of the WAVE regulatory complex and signal integration. Semin Cell Dev Biol (2013) 0.96
Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). J Biol Chem (2011) 0.96
The tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cells. PLoS One (2012) 0.95
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics (2011) 0.95
(-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther (2011) 0.94
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis (2011) 0.93
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood (2013) 0.93
Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res (2011) 0.93
Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation. Int J Oncol (2010) 0.93
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood (2010) 0.93
Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility. J Biol Chem (2013) 0.93
Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory region supports an SH3-dominant activation mechanism. J Biol Chem (2010) 0.93
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy. Cancer Lett (2012) 0.93
The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet (2011) 0.92
Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor. Endocrinology (2012) 0.92
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis (2012) 0.92
Active site profiling reveals coupling between domains in SRC-family kinases. Nat Chem Biol (2012) 0.91
Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors. J Am Chem Soc (2012) 0.90
Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol (2012) 0.90
Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene (2012) 0.90
Macrophage motility requires distinct α5β1/FAK and α4β1/paxillin signaling events. J Leukoc Biol (2010) 0.90
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget (2012) 0.90
CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis. Oncogene (2014) 0.89
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res (2012) 0.89
Systems microscopy approaches to understand cancer cell migration and metastasis. Cell Mol Life Sci (2010) 0.89
STATs: An Old Story, Yet Mesmerizing. Cell J (2015) 0.89
Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. Cancer Res (2011) 0.89
Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget (2014) 0.89
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis (2015) 0.89
Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Res (2014) 0.88
Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol (2013) 0.88
Increased activation of the PI3K/AKT pathway compromises decidualization of stromal cells from endometriosis. J Clin Endocrinol Metab (2011) 0.88
The myotubularin family of lipid phosphatases in disease and in spermatogenesis. Biochem J (2011) 0.88
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics. Adv Exp Med Biol (2012) 0.88
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer (2011) 0.88
Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension. J Biol Chem (2014) 0.88
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorg Med Chem Lett (2013) 0.87
ATRA-induced HL-60 myeloid leukemia cell differentiation depends on the CD38 cytosolic tail needed for membrane localization, but CD38 enzymatic activity is unnecessary. Exp Cell Res (2010) 0.87
Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget (2015) 0.87
Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget (2014) 0.86
The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. MAbs (2013) 0.86
Signal integration and gene induction by a functionally distinct STAT3 phosphoform. Mol Cell Biol (2014) 0.86
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biol Ther (2012) 0.86
Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene (2010) 0.86
Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel) (2011) 0.86
Src signaling pathways in prostate cancer. Cancer Metastasis Rev (2014) 0.86
Molecular alterations associated with osteosarcoma development. Sarcoma (2012) 0.86
A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene (2014) 0.86
Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene (2016) 0.85
Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI. PLoS One (2015) 0.85
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase. PLoS One (2011) 0.85
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS. J Exp Med (1911) 29.44
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem (1996) 10.08
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature (1976) 9.81
Crystal structure of the Src family tyrosine kinase Hck. Nature (1997) 7.66
Three-dimensional structure of the tyrosine kinase c-Src. Nature (1997) 7.62
Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol (1989) 6.31
A renaissance for SRC. Nat Rev Cancer (2004) 6.27
A novel viral oncogene with structural similarity to phospholipase C. Nature (1988) 5.84
Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell (1990) 4.83
Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta (2007) 4.74
Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain. Cell (1987) 4.63
SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol (2000) 4.30
Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol (1989) 4.08
A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol (1986) 4.00
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 3.86
The hunting of the Src. Nat Rev Mol Cell Biol (2001) 3.64
Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene (2004) 3.63
Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res (1993) 3.62
RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol Biol Cell (2001) 3.54
Role of Src expression and activation in human cancer. Oncogene (2000) 3.41
Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev (2001) 3.27
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology (2003) 3.17
Differential regulation of cell motility and invasion by FAK. J Cell Biol (2003) 3.15
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet (1999) 2.84
Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol (2002) 2.84
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure (2005) 2.78
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res (2005) 2.76
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev (1995) 2.72
Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science (1992) 2.56
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J (1993) 2.46
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia (2008) 2.44
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature (1992) 2.39
Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res (1995) 2.23
Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A (2003) 2.21
Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res (2000) 2.14
Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene (2004) 2.12
Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol (2002) 2.09
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol (1997) 1.97
Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem (1996) 1.97
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res (2007) 1.96
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat (2005) 1.94
Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J Cell Biol (2003) 1.90
Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochim Biophys Acta (2004) 1.85
Tyrosine phosphorylation and src family kinases control keratinocyte cell-cell adhesion. J Cell Biol (1998) 1.84
Coordination of cell polarization and migration by the Rho family GTPases requires Src tyrosine kinase activity. Curr Biol (2001) 1.81
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol (2007) 1.79
Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol (2000) 1.77
The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res (2006) 1.71
c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene (2006) 1.69
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer (2006) 1.67
Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res (2009) 1.65
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell (2007) 1.61
Targeting Src in breast cancer. Ann Oncol (2008) 1.57
Oxidized phospholipids increase interleukin 8 (IL-8) synthesis by activation of the c-src/signal transducers and activators of transcription (STAT)3 pathway. J Biol Chem (2004) 1.52
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res (2007) 1.51
Src continues aging: current and future clinical directions. Clin Cancer Res (2007) 1.50
pp60c-src activation in lung adenocarcinoma. Eur J Cancer (2003) 1.49
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res (2007) 1.45
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res (2006) 1.42
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer (2006) 1.41
Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J (1996) 1.37
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res (1996) 1.36
ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res (2005) 1.35
Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res (2005) 1.34
Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res (2002) 1.33
Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med (2002) 1.31
Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res (2005) 1.31
SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res (2005) 1.29
Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front Biosci (1997) 1.28
Role of the cytoplasmic tyrosines of beta 1A integrins in transformation by v-src. Proc Natl Acad Sci U S A (2001) 1.28
Phosphorylation of beta3 integrin controls ligand binding strength. J Biol Chem (2001) 1.25
Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem (2001) 1.24
Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A (2000) 1.22
Src-related protein tyrosine kinases in hematopoiesis. Blood (1999) 1.19
Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer (1992) 1.15
Src as a potential therapeutic target in non-small-cell lung cancer. Ann Oncol (2008) 1.12
TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem (2001) 1.08
Identification of Src transformation fingerprint in human colon cancer. Oncogene (2002) 1.07
Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int J Mol Med (2007) 1.04
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther (2006) 1.02
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer (2006) 0.93
Inhibitory role of Src family tyrosine kinases on Ca2+-dependent insulin release. Am J Physiol Endocrinol Metab (2006) 0.82
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Stat3 regulates genes common to both wound healing and cancer. Oncogene (2005) 2.80
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res (2005) 2.19
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther (2005) 1.75
Direct repression of the Mcl-1 promoter by E2F1. Oncogene (2002) 1.60
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol (2007) 1.49
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics (2006) 1.38
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther (2007) 1.30
JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther (2011) 1.29
Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther (2003) 1.16
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res (2012) 1.16
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res (2010) 1.10
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A (2013) 1.09
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08
MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol (2009) 1.07
A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol (2010) 1.07
Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem (2012) 1.06
Dasatinib in solid tumors. Expert Opin Investig Drugs (2010) 1.06
Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol (2010) 1.05
EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol (2005) 1.01
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A (2014) 0.99
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer (2008) 0.98
Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. PLoS One (2010) 0.98
Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev (2012) 0.98
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol (2013) 0.97
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer (2014) 0.95
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol (2013) 0.93
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics (2002) 0.92
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol (2014) 0.91
Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer (2010) 0.91
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest (2016) 0.89
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther (2009) 0.89
An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. FASEB J (2011) 0.88
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother (2013) 0.87
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem (2012) 0.86
Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer (2004) 0.84
Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract (2012) 0.83
Effects of IFN-gamma and Stat1 on gene expression, growth, and survival in non-small cell lung cancer cells. J Interferon Cytokine Res (2007) 0.81
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol (2014) 0.81
A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. J Proteome Res (2013) 0.81
The NAD+ synthesis enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT1) regulates ribosomal RNA transcription. J Biol Chem (2013) 0.81
IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry. Bioinformatics (2008) 0.80
Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest (2005) 0.79
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol (2011) 0.78
TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis (2013) 0.78
Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit. Int J Radiat Oncol Biol Phys (2011) 0.78
Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochem Pharmacol (2010) 0.78
Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer. Expert Opin Ther Targets (2013) 0.77
The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics. Cancer Discov (2011) 0.76
Healthcare providers' knowledge and attitudes about rapid tissue donation (RTD): phase one of establishing a rapid tissue donation programme in thoracic oncology. J Med Ethics (2013) 0.75
The ethical imperative of risk disclosure in research: the answer is always yes. Am J Bioeth (2014) 0.75